Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01559844
Registration number
NCT01559844
Ethics application status
Date submitted
5/03/2012
Date registered
21/03/2012
Date last updated
27/07/2016
Titles & IDs
Public title
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Query!
Scientific title
An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Query!
Secondary ID [1]
0
0
P7977-2025
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hepatitis C
0
0
Query!
Hepatocellular Carcinoma
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Cancer
0
0
0
0
Query!
Liver
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sofosbuvir
Treatment: Drugs - Ribavirin
Experimental: SOF+RBV - Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
Treatment: Drugs: Sofosbuvir
Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
Treatment: Drugs: Ribavirin
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and = 75 kg = 1200 mg)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12
Query!
Assessment method [1]
0
0
pTVR was defined as HCV RNA < the lower limit of quantification (LLOQ, ie, 25 mL/IU) at Week 12 after transplant.
Query!
Timepoint [1]
0
0
Posttransplant Week 12
Query!
Primary outcome [2]
0
0
Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sofosbuvir Prior to Receiving Transplant
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 48 weeks prior to transplant
Query!
Primary outcome [3]
0
0
Percentage of Participants With Graft Loss Following Transplant
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 48 weeks following transplant
Query!
Primary outcome [4]
0
0
Number of Participants Who Died
Query!
Assessment method [4]
0
0
Treatment-emergent deaths were those that occurred while taking study drug or to the minimum of 1) date of transplantation, 2) retreatment 1st dose date, or 3) last dose date + 30 days.
Only those participants who underwent liver transplantation were analyzed for death post-transplantation.
Query!
Timepoint [4]
0
0
Up to 48 weeks following transplant
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48
Query!
Assessment method [1]
0
0
pTVR was defined as HCV RNA < the lower limit of quantification (LLOQ, ie, 25 mL/IU) at the relevant time point after transplant.
Query!
Timepoint [1]
0
0
Up to 48 weeks following transplant
Query!
Secondary outcome [2]
0
0
Percentage of Participants With HCV RNA < LLOQ (ie, 25 mL/IU) During Treatment Through Week 48
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 48 weeks prior to transplant
Query!
Secondary outcome [3]
0
0
HCV RNA and Change From Baseline in HCV RNA Through Week 8
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 8 weeks prior to transplant
Query!
Secondary outcome [4]
0
0
Proportion of Participants With Virologic Failure Prior to Transplant
Query!
Assessment method [4]
0
0
Virologic failure (VF) in the pretransplant phase was defined by:
Breakthrough (HCV RNA = 25 IU/ml after having previously had HCV RNA < 25 IU/ml, while on treatment)
Rebound (breakthrough or > 1 log10 IU/ml increase in HCV RNA from nadir while on treatment)
Non-response (HCV RNA = 25 IU/ml through 8 weeks of treatment)
Pre-transplant relapse (HCV RNA = 25 IU/ml during the Pre-Transplant off-treatment follow-up period after having achieved HCV RNA < 25 IU/ml at last observed HCV RNA on treatment)
Query!
Timepoint [4]
0
0
Up to 48 weeks prior to transplant
Query!
Eligibility
Key inclusion criteria
1. Willing and able to provide written informed consent
2. Males or females, age > 18 years old
3. Males must agree to consistently and correctly use a condom while their female partner
agrees to use an approved form of birth control from the date of screening until 7
months after their last dose of ribavirin.
4. Confirmation of chronic HCV infection documented by at least one measurement of serum
HCV RNA above the LLOQ measured at screening, and at least one of the following:
- Positive anti-HCV antibody test, HCV RNA or HCV genotyping test at least 6 months
prior to the baseline/Day 1 visit together with positive HCV RNA test and
anti-HCV antibody at the time of screening, or
- Positive HCV RNA test and anti-HCV antibody test at the time of screening
together with either a liver biopsy consistent with chronic HCV infection (or a
liver biopsy performed before enrollment with evidence of chronic HCV infection,
such as the presence of fibrosis)
5. HCV RNA > 10^4 IU/mL at screening
6. Patients meeting the MILAN criteria undergoing liver transplant for HCC secondary to
HCV with a MELD of < 22 and a HCC weighted MELD of = 22.
7. Child-Pugh Score (CPT) = 7
8. Planned management of the subject to meet United Network for Organ Sharing (UNOS)
criteria, with imaging studies made available for review if required.
9. Has not been treated with any investigational drug or device within 30 days of the
screening visit.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Females of child-bearing potential who is pregnant or nursing
2. Prior exposure to a direct-acting antiviral targeting the HCV nonstructural (NS)5B
polymerase
3. Any transplant patient who has agreed to a liver transplant from a live donor.
4. Participants requiring planned induction therapy with biologics posttransplantation or
with a posttransplantation immunosuppressive regimen not consistent with the following
within the first 12 weeks posttransplant:
- Solumedrol/Prednisone (tapering over approximately 7 days)
- Tacrolimus (maintaining a serum level of 5 12 ng/mL)
- Mycophenolate mofetil (up to 2 g/day)
- Introduction of new maintenance immunosuppressants different from the above list
is disallowed except in consultation during the first 12 weeks posttransplant
5. Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy,
hepatorenal syndrome and hepatopulmonary syndrome, among other signs of decompensated
cirrhosis.
6. Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease,
alpha-1 antitrypsin deficiency, cholangitis)
7. Infection with hepatitis B virus (HBV) or HIV
8. Contraindications to RBV therapy
9. Chronic use of systemically administered immunosuppressive agents (eg, prednisone
equivalent > 10 mg/day) in the pretransplant treatment period.
10. History of previous solid organ transplantation
11. Evidence of renal impairment (CLcr < 60 mL/min) calculated by the Cockcroft-Gault
equation.
12. History or current evidence of psychiatric illness, immunologic disorder,
hemoglobinopathy, pulmonary or cardiac disease, porphyria, or poorly controlled
diabetes, cancer other than HCC, or a history of malignancy that in the opinion of the
investigator makes the patient unsuitable for the study. Patients with clinical signs
or symptoms of acute pancreatitis with elevated lipase (at Screening or during the
screening period)
13. Known hypersensitivity to RBV, the study investigational medicinal product, the
metabolites, or formulation excipients
14. History of having received any systemic antineoplastic (including sorafenib) or
immunomodulatory treatment (including radiation) within 6 months prior to the first
dose of study drug or the expectation that such treatment will be needed at any time
during the study (excluding a local regional therapy such as TACE).
15. Treatment with Transcatheter arterial chemoembolization (TACE) or radio frequency
ablation (RFA) within 30 days prior to the first dose.
16. Participation in a clinical study with an investigational drug, biologic, or device
within 3 months prior to first dose administration at the baseline/Day 1 Visit.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
61
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
New Zealand
Query!
State/province [10]
0
0
Auckland
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Pamplona
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective is to determine if the administration of a combination of sofosbuvir
(SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular
carcinoma (HCC) meeting the MILAN criteria prior to undergoing liver transplantation could
prevent post-transplant re-infection as determined by a sustained post-transplant virological
response (HCV RNA < LLoQ) at 12 weeks post-transplant.
Participants will enroll in the pretransplant treatment phase (24 or 48 weeks). Participants
enrolling for 24 weeks in the pretransplant treatment phase may receive treatment for up to
an additional 24 weeks in the pretransplant retreatment phase. Participants enrolling for 48
weeks in the pretransplant treatment will have a second baseline at Week 24 for combined
analysis in the pretransplant retreatment phase.
Participants who undergo liver transplant will stop all study drug 24 hours prior to
transplant, and enter a 48-week follow-up phase to monitor for recurrent HCV infection.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01559844
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jill Denning, MA
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01559844
Download to PDF